There has been an unprecedented demand on biopharma manufacturers to produce an mRNA vaccine in an accelerated timeline. Given the considerable number of variables throughout the production workflow, new flexible and robust manufacturing solutions are required to accelerate scale-up and standardize GMP manufacturing processes.
This presentation shares:
Insights into new platform technologies that increase efficiency to enable rapid scale-up and large-scale manufacturing of mRNA vaccines and therapeutics
How to improve operational flexibility by expanding single-use technology to LNPs
Strategies to increase manufacturing capacity during clinical and commercial production
Learn more at www.cytiva.com
6 окт 2024
